Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
6 evidence topics · 7 sources
Lesion location: foveal and non-foveal subgroups, stratified combined analysis (topline data)
Lesion location: final data with nominal p values within each subgroup
| Lesion location | Sham | Vonaprument every other month | Vonaprument every month |
|---|---|---|---|
| Foveal, participants with loss | “25.0%”“11/44” | “16.3%”“8/49” | “5.9%”“3/51” |
| Foveal, nominal p value versus sham | “---” | “.3003” | “.0088” |
| Non-foveal, participants with loss | “17.8%”“8/45” | “2.3%”“1/43” | “5.3%”“2/38” |
| Non-foveal, nominal p value versus sham | “---” | “.0168” | “.0810” |
Subfoveal retinal pigment epithelium lesions: post hoc analysis
“76% Risk Reduction Vonaprument EM” (opens the source at this quote in a new tab)
“HR (CI) = 0.242 (0.067 to 0.881); Nominal p = .0204*” (opens the source at this quote in a new tab)
“41% Risk Reduction Vonaprument EOM” (opens the source at this quote in a new tab)
“HR (CI) = 0.504 (0.225 to 1.555); Nominal p = .2784” (opens the source at this quote in a new tab)
Baseline low-luminance visual deficit: healthier and less healthy retina, stratified combined analysis (topline data)
| Baseline LLVD | Sham | Vonaprument every month | Vonaprument every other month | Vonaprument pooled |
|---|---|---|---|---|
| Below 30 (healthier) | “16.9%”“(10/59)” | “0.0%”“(0/56)” | “6.3%”“(3/48)” | “2.9%”“(3/104)” |
| 30 or higher (less healthy) | “30.8%”“(8/26)” | “16.1%”“(5/31)” | “16.3%”“(7/43)” | “16.2%”“(12/74)” |
| Stratified p value versus sham | “--” | “0.0016” | “0.029” | “0.0009” |